EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021.doi:10.1200/JCO.2024.42.16_suppl.e1350563e13505#Background:Lung cancer is the leading cause of cancer-related mortality worldwide. Epidermal ...
Introduction: 1L pembro + chemo significantly improved OS vs chemo for metastatic sqNSCLC in the KEYNOTE-407 study. Poly(ADP-ribose) polymerase inhibitors (PARPi) can upregulate PD-L1 expression and promote immune-mediated response, which may increase the efficacy of antiPD-(L)1based therapies....
68P Phase II results of ivonescimab (ivo) a novel PD-1/VEGF bispecific in combination with chemotherapy for first-line treatment of patients (pts) with advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC) 来自 dx.doi.org 喜欢 0 阅读量: 25 ...
H48Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practicedoi:10.1093/annonc/mdv343.48A. CortelliniG. Bruera
aspartate aminotransferase increased and alanine aminotransferase increased (TIS arm), and alopecia, anemia and neutrophil count decreased (D arm).Conclusions: TIS prolonged OS, consistent with the overall ITT population, with a favorable safety profile in patients with advanced non-sq NSCLC who progres...
Horn L. Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs) [webcast on the Internet].2015 Sep 28. [cited 2015 Nov 19]. (Presented...
Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands. Most patients diagnosed with non-small cell lung cancer (NSCLC) die within the first few years after diagnosis. However, only little is known about those w... ML Janssen-Heijnen,LN Van Steenbergen,E ...
Cyclin D1 is part of the molecular system regulating the cell cycle G1 to S transition point. Its overexpression, a common finding in carcinomas of the breast, oesophagus, and head and neck, has also been demonstrated in a high percentage of non-small cell lung carcinomas (NSCLCs). The...
O3-097 * PHASE II STUDY OF BEVACIZUMAB PLUS CBDCA/PAC AS FIRST LINE CHEMOTHERAPY FOR NON-SQ NSCLC WITH MALIGNANT PLEURAL EFFUSIONAnnals of Oncology
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for advanced non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations. However, there have been little evidence-based studies of gefitinib in combination with platinum-...